Barclays
RCKT icon

Barclays’s Rocket Pharmaceuticals RCKT Stock Holding History

Barclays’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$377K – 5502
2024
Q4 		$377K Hold
30,000
– – ﹤0.01% 3992
2024
Q3 		$554K Buy
+30,000
New +$614K ﹤0.01% 3711
2024
Q2 		– Sell
-47,400
Closed -$1.28M – 5220
2024
Q1 		$1.28M Hold
47,400
– – ﹤0.01% 2921
2023
Q4 		$1.42M Buy
+47,400
New +$1.05M ﹤0.01% 3186
2017
Q1 		– Sell
-5,000
Closed -$122K – 6935
2016
Q4 		$122K Buy
+5,000
New +$143K ﹤0.01% 4605

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Barclays's RCKT Position: Q2 2026 in Review

Barclays increased its Rocket Pharmaceuticals (RCKT) stake by 37% in Q2 2026, buying an estimated $20.4K and bringing the position to 22,716 shares worth $77.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4157.

Barclays first reported a position in RCKT in Q4 2015 and has held it in 42 quarters since. The position peaked at $9.59M in Q4 2021. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Barclays held 22,716 shares of Rocket Pharmaceuticals worth $77.7K as of Q2 2026.
  • Barclays bought 6,138 Rocket Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4157 holding.
  • Barclays first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • Barclays's Rocket Pharmaceuticals position peaked at $9.59M in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.